AbbVie Reports Results of Rinvoq (upadacitinib) as Monotherapy in a P-III Measure Up 2 Study for Atopic Dermatitis

 AbbVie Reports Results of Rinvoq (upadacitinib) as Monotherapy in a P-III Measure Up 2 Study for Atopic Dermatitis

Shots:

  • The P-III Measure Up 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adults and adolescents aged 12-18yrs. or older with mod. to sev. AD who are candidates for systemic treatment. Placebo patients were switched to either upadacitinib (15/30mg) @16wks.
  • The study met its co-1EPs @16wks. i.e. improvement in EASI 75 (60%/73% vs 13%), patient achieving vIGA-AD 0/1 (39%/52% vs 5%); reduction in itch (42%/60% vs 9%); Improvement in Worst Pruritus NRS≥4 (42%/60% vs 9%) respectively
  • Rinvoq (qd) is a selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases and has received the US FDA’s approval for patients with mod. to sev. active RA having inadequate response or intolerance to MTX. The therapy is under P-III study for AD, RA, PsA, axSpA, CD, UC and giant cell arteritis

Click here to read full press release/ article | Ref: PRNewswire | Image: WSJ

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post